<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03588494</url>
  </required_header>
  <id_info>
    <org_study_id>NSOG001</org_study_id>
    <nct_id>NCT03588494</nct_id>
  </id_info>
  <brief_title>Endostar in Combination With Chemoradiotherapy in Patient With Advanced Non-small Cell Lung Cancer</brief_title>
  <official_title>Recombinant Human Endostatin (Endostar) Combined With Concurrent Chemoradiotherapy for Advanced Non-small Cell Lung Cancer: A Multicenter, Randomized, Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Afﬁliated Hospital of North Sichuan Medical College</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jiangsu Simcere Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Afﬁliated Hospital of North Sichuan Medical College</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the safety and efficacy recombinant human endostatin(endostar) durative
      transfusion combined with cocurrent chemoradiotherapy in advanced non-small cell lung
      cancer(NSCLC).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2018</start_date>
  <completion_date type="Anticipated">September 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients were randomly assigned to a regimen of W1-CCRT(one treatment cycle of intravenous pump of recombinant human endostatin before chemoradiotherapy), or W2-CCRT(two treatment cycle of intravenous pump of recombinant human endostatin before chemoradiotherapy), or CCRT.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression free survival (PFS)</measure>
    <time_frame>4 years</time_frame>
    <description>Evaluate the effect of chemoradiotherapy with or without recombinant human endostatin on progression free survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival(OS)</measure>
    <time_frame>4 years</time_frame>
    <description>comparison to maintenance chemoradiotherapy alone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-related toxicity</measure>
    <time_frame>4 years</time_frame>
    <description>Toxicity and adverse events related to the inventions</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">318</enrollment>
  <condition>Quality of Life</condition>
  <arm_group>
    <arm_group_label>concurrent chemoradiotherapy (CCRT)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Chemotherapy: Cisplatin (50 mg/m2) on days 1, 8, 29, and 36 and etoposide (50mg/m2) on days 1～5 and 29～33.
Radiotherapy: Thoracic radiotherapy (TRT) started with a linear accelerator (6MV-X) on the first day of chemotherapy.A minimum dose of 60 Gy (2 Gy per fraction, Monday～Friday) was delivered, and a range of 60-66 Gy in 2 Gy fractions was allowed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>W1-CCRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Endostar(15 mg/m2) was durative transfused every 24 hours for 5 days during the normalization window of the first chemoradiotherapy cycle(days -5～-1).
Chemotherapy: Cisplatin (50 mg/m2) on days 1, 8, 29, and 36 and etoposide (50mg/m2) on days 1～5 and 29～33.
Radiotherapy: Thoracic radiotherapy (TRT) started with a linear accelerator (6MV-X) on the first day of chemotherapy.A minimum dose of 60 Gy (2 Gy per fraction, Monday～Friday) was delivered, and a range of 60-66 Gy in 2 Gy fractions was allowed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>W2-CCRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Endostar(15 mg/m2) was durative transfused every 24 hours for 5 days during the normalization window of the first and the second chemoradiotherapy cycles(days -5～-1 and 24～28).
Chemotherapy: Cisplatin (50 mg/m2) on days 1, 8, 29, and 36 and etoposide (50mg/m2) on days 1～5 and 29～33.
Radiotherapy: Thoracic radiotherapy (TRT) started with a linear accelerator (6MV-X) on the first day of chemotherapy.A minimum dose of 60 Gy (2 Gy per fraction, Monday～Friday) was delivered, and a range of 60-66 Gy in 2 Gy fractions was allowed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>concurrent chemoradiotherapy (CCRT)</intervention_name>
    <description>Chemotherapy: Cisplatin (50 mg/m2) on days 1, 8, 29, and 36 and etoposide (50mg/m2) on days 1～5 and 29～33.
Radiotherapy: Thoracic radiotherapy (TRT) started with a linear accelerator (6MV-X) on the first day of chemotherapy.A minimum dose of 60 Gy (2 Gy per fraction, Monday～Friday) was delivered, and a range of 60-66 Gy in 2 Gy fractions was allowed.</description>
    <arm_group_label>W1-CCRT</arm_group_label>
    <arm_group_label>W2-CCRT</arm_group_label>
    <arm_group_label>concurrent chemoradiotherapy (CCRT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Endostar for one cycle</intervention_name>
    <description>Endostar(15mg/m2) was durative transfused during the normalization window of the first chemoradiotherapy cycle(days -5～-1).</description>
    <arm_group_label>W1-CCRT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Endostar for two cycles</intervention_name>
    <description>Endostar(15mg/m2) was durative transfused during the normalization window of the first and the second chemoradiotherapy cycles(days -5～-1 and 24～28).</description>
    <arm_group_label>W2-CCRT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Male or female patients, age: 18-70 years of age

          -  2. Pathology was diagnosed as non-small cell lung cancer. According to the Tumor Node
             Metastasis（TNM）stage of the 8th edition of the International Association for the Study
             of Lung Cancer in 2017, And the pathological stage was identified as stage IIIa-b.

          -  3. No previous chest radiotherapy and radiotherapy, immunotherapy or biological
             therapy.

          -  4. Eastern Cooperative Oncology Group (ECOG) test scored 0-1.

          -  5. Serum hemoglobin ≥ 100g/L, platelet ≥ 100 × 109/L, absolute number of neutrophils ≥
             1.5 × 109/L.

          -  6. Serum creatinine ≤ 1.25 times the upper limit of normal(UNL) or creatinine
             clearance ≥ 60 mL/min.

          -  7. Serum bilirubin ≤ 1.5 times UNL, Aspartate aminotransferase (AST) and adenosine
             triphosphate (ALT) ≤ 2.5 times UNL, alkaline phosphatase ≤ 5 times UNL.

          -  8. Forced vital capacity rate of one second（FEV1）＞0.8 litre.

          -  9. Coagulation function is normal

          -  10. lesions are measurable according to the Response Evaluation Criteria in Solid
             Tumors Version 1.1(RECIST1.1)standard

          -  11. Sign the inform consent form with good compliance

        Exclusion Criteria:

          -  1. Carcinoid or small cell lung cancer

          -  2. Patients with any distant metastasis

          -  3. patients with previous or current malignancy, except for skin non-melanoma or
             carcinoma in situ in the cervix

          -  4. Any other disease or condition is a contraindication to chemoradiation (eg, active
             infection, 6 months after myocardial infarction, symptomatic heart disease including
             unstable angina, congestive heart failure or uncontrolled arrhythmia,
             immunosuppressive therapy).

          -  5. Pregnancy or breastfeeding women

          -  6. Women who may be pregnant but are unwilling to take appropriate contraception

          -  7. Hereditary bleeding or coagulopathy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daiyuan Ma, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Afﬁliated Hospital of North Sichuan Medical College</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daiyuan Ma, M.D</last_name>
    <phone>868172246171</phone>
    <email>angenpn@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Affiliated Hospital of North Sichuan Medical College</name>
      <address>
        <city>Nanchong</city>
        <state>Sichuan</state>
        <zip>600000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Daiyuan Ma, M.D</last_name>
      <phone>868172246171</phone>
      <email>angenpn@gmail.com</email>
    </contact>
    <investigator>
      <last_name>xin hu, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>xiangdong fang, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>June 23, 2018</study_first_submitted>
  <study_first_submitted_qc>July 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 17, 2018</study_first_posted>
  <last_update_submitted>July 4, 2018</last_update_submitted>
  <last_update_submitted_qc>July 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Afﬁliated Hospital of North Sichuan Medical College</investigator_affiliation>
    <investigator_full_name>DaiYuan Ma</investigator_full_name>
    <investigator_title>Director of Cancer Center</investigator_title>
  </responsible_party>
  <keyword>Recombinant human endostatin</keyword>
  <keyword>NSCLC</keyword>
  <keyword>chemoradiotherapy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endostar protein</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

